Key Takeaways
CMB International Securities on Tuesday raised its target price for CStone Pharmaceuticals (02616.HK) by 131.5 percent to HK$16.9, citing significant upside for its novel drug candidate CS2009.
"The market is re-pricing the stock based on CS2009's excellent early data and anticipating potential business development," the brokerage said in its research report, maintaining an 'Overweight' rating on the stock.
The new price target of HK$16.9 is a substantial increase from the previous HK$7.3. The upgrade is primarily based on a higher asset valuation for CS2009, a tri-specific antibody targeting PD-1, VEGF, and CTLA-4. CMB International noted that despite uncertainties in future clinical development, CStone's management has a clear research and development strategy.
The report highlights the potential for CStone to engage in deep cooperation with large overseas pharmaceutical companies. According to CMB International, CStone's management expressed strong confidence in the Phase 2 dose expansion and future Phase 3 multi-regional clinical trials for the tri-specific antibody.
This significant target price revision suggests a strong belief in CS2009's ability to stand out in a competitive field. Investors will be watching for further clinical data and any news of potential partnerships as the next major catalysts for the company.
This article is for informational purposes only and does not constitute investment advice.
